Bi-weekly capecitabine and oxaliplatin plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

ABSTRACT: Interventions: Bi-weekly XELOX+bevacizumab Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622609 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR